IFNB1 and myeloid sarcoma: Larger studies identifying the mechanisms underlying the relationship between T cell activation induced by IFN-β and relapse risk will be important not only for improving our understanding of this immunomodulatory MS therapy, but also for understanding what may be a natural, immunoregulatory role of type I IFN activity in MS.